Skip to content

Study · In vitro (cells) · 2020

7 results

Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.

Wenjing H, Shao Y, Yu Y, Huang W, Feng G, Li J

The Prostate22 Jan 2020Cited by 27 (Europe PMC)

PMID31967357 (opens in a new tab)DOI10.1002/pros.23951 (opens in a new tab)PepBankPUB-31967357
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In prostate cancer cells, adding exendin‑4 to enzalutamide suppressed tumor growth compared with enzalutamide alone.

    In plain wordsIn cells, adding exendin‑4 to enzalutamide reduced tumor growth compared with enzalutamide alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTumor growth
    Study

    n: not reported in source

    LNCap and CWR22RV1 prostate cancer cells
    Comparator
    Enzalutamide alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4 in combination with enzalutamide dramatically suppressed tumor growth of prostate cancer cells compared to enzalutamide alone;
    1 context sentence
    Summary · context
    LNCap and CWR22RV1 cell lines, as well as mice bearing xenografts formed from the two cells, were used.
  2. 02LabIn vitro (cells)Mechanism

    In prostate cancer cells, exendin‑4 antagonized enzalutamide-induced invasion compared with enzalutamide alone.

    In plain wordsIn cells, exendin‑4 reduced enzalutamide-induced invasion compared with enzalutamide alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCell invasion
    Study

    n: not reported in source

    LNCap and CWR22RV1 prostate cancer cells
    Comparator
    Enzalutamide alone
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    exendin-4 is capable of antagonizing enzalutamide-induced invasion and migration of both prostate cancer cells (P < .05).
    1 context sentence
    Summary · context
    LNCap and CWR22RV1 cell lines, as well as mice bearing xenografts formed from the two cells, were used.
  3. 03LabIn vitro (cells)Mechanism

    In prostate cancer cells, exendin‑4 antagonized enzalutamide-induced migration compared with enzalutamide alone.

    In plain wordsIn cells, exendin‑4 reduced enzalutamide-induced migration compared with enzalutamide alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCell migration
    Study

    n: not reported in source

    LNCap and CWR22RV1 prostate cancer cells
    Comparator
    Enzalutamide alone
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    exendin-4 is capable of antagonizing enzalutamide-induced invasion and migration of both prostate cancer cells (P < .05).
    1 context sentence
    Summary · context
    LNCap and CWR22RV1 cell lines, as well as mice bearing xenografts formed from the two cells, were used.
  4. 04LabIn vitro (cells)Mechanism

    In prostate cancer models, adding exendin‑4 to enzalutamide reduced enzalutamide-triggered Akt levels.

    In plain wordsIn lab tests, adding exendin‑4 to enzalutamide reduced Akt levels triggered by enzalutamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAkt levels
    Study

    n: not reported in source

    LNCap and CWR22RV1 prostate cancer cells
    Comparator
    Enzalutamide alone
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, the combination treatment significantly reduced Akt and mTOR levels that were triggered by enzalutamide administration,
    1 context sentence
    Summary · context
    LNCap and CWR22RV1 cell lines, as well as mice bearing xenografts formed from the two cells, were used.
  5. 05LabIn vitro (cells)Mechanism

    In prostate cancer models, adding exendin‑4 to enzalutamide reduced enzalutamide-triggered mTOR levels.

    In plain wordsIn lab tests, adding exendin‑4 to enzalutamide reduced mTOR levels triggered by enzalutamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasemTOR levels
    Study

    n: not reported in source

    LNCap and CWR22RV1 prostate cancer cells
    Comparator
    Enzalutamide alone
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, the combination treatment significantly reduced Akt and mTOR levels that were triggered by enzalutamide administration,
    1 context sentence
    Summary · context
    LNCap and CWR22RV1 cell lines, as well as mice bearing xenografts formed from the two cells, were used.
  6. 06LabIn vitro (cells)Mechanism

    In prostate cancer models, adding exendin‑4 to enzalutamide further decreased nuclear androgen receptor localization versus enzalutamide alone.

    In plain wordsIn lab tests, adding exendin‑4 to enzalutamide reduced nuclear androgen receptor localization more than enzalutamide alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseNuclear androgen receptor localization with combination
    Study

    n: not reported in source

    LNCap and CWR22RV1 prostate cancer cells
    Comparator
    Enzalutamide alone
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    caused a further decrease in nuclear AR localization compared with the enzalutamide as a monotherapy (P < .5)
    1 context sentence
    Summary · context
    LNCap and CWR22RV1 cell lines, as well as mice bearing xenografts formed from the two cells, were used.
  7. 07LabIn vitro (cells)Mechanism

    In prostate cancer models, exendin‑4 alone did not affect nuclear androgen receptor localization.

    In plain wordsIn lab tests, exendin‑4 alone did not change nuclear androgen receptor localization.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeNuclear androgen receptor localization with exendin-4 alone
    Study

    n: not reported in source

    LNCap and CWR22RV1 prostate cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    though exendin-4 treatment alone showed no effect on nuclear AR.
    1 context sentence
    Summary · context
    LNCap and CWR22RV1 cell lines, as well as mice bearing xenografts formed from the two cells, were used.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.